Congenital Heart Defect Pipeline Analysis Report 2026

Report Coverage

The Congenital Heart Defect Pipeline Analysis Report by Expert Market Research gives comprehensive insights into congenital heart defect therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for congenital heart defect. The congenital heart defect report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The congenital heart defect pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with congenital heart defect treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to congenital heart defect.

Read more about this report - Request a Free Sample

Congenital Heart Defect Pipeline Outlook

Advances in catheter-based technologies are strengthening the congenital heart defect pipeline, particularly for patients with complex anatomy and limited treatment options. In January 2026, the FDA approved Stereotaxis’ MAGiC Ablation Catheter for mapping and treating supraventricular tachycardia in congenital heart disease patients with difficult vascular or chamber access. This approval supports development of minimally invasive devices, precision mapping systems, and specialized pediatric and adult congenital heart interventions during the forecast period across hospitals, pediatric centers, and specialized cardiac programs nationwide.

Congenital Heart Defect Epidemiology

Congenital heart defect (CHD) is the most common birth defect worldwide, affecting approximately 8-10 live births per 1,000 newborns, while nearly 1% of births in the United States are diagnosed with CHD, representing about 40,000 infants annually. Approximately 25% of affected newborns have critical congenital heart defects requiring intervention within the first year of life. Advances in prenatal screening, neonatal diagnosis, and surgical management have improved survival, leading to a growing population of children and adults living with CHD.

Congenital Heart Defect – Pipeline Therapeutic Assessment

Congenital Heart Defect Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total congenital heart defect clinical trials. Early Phase I (3.85%), Phase I (19.23%), Phase II (23.08%), Phase III (19.23%), and Phase IV (34.62%), reflecting the distribution of drug candidates across different stages of clinical development.

Congenital Heart Defect Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the congenital heart defect pipeline analysis include small molecules, gene therapies and cell therapies. The congenital heart defect report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for congenital heart defect. In December 2025, the FDA cleared Abbott’s Amplatzer Piccolo Delivery System for placing the Piccolo Occluder in premature infants with patent ductus arteriosus. The delivery system received clearance, whereas the occluder itself was approved in 2019.

Congenital Heart Defect Clinical Trials – Key Players

The EMR report for the congenital heart defect pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed congenital heart defect therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in congenital heart defect clinical trials:

• HeartWorks, Inc.
• Stealth BioTherapeutics Inc.
• Metcela Inc.
• Boehringer Ingelheim
• ACE Pharmaceuticals BV
• Actelion Pharmaceuticals Ltd.
• Johnson & Johnson Innovative Medicine
• Merck & Co., Inc.
• Bayer AG
• Pfizer Inc.
• Eli Lilly and Company
• Tenaya Therapeutics, Inc.

Congenital Heart Defect – Emerging Drugs Profile

Key Questions Answered in the Congenital Heart Defect Pipeline Insight Report

• Which companies/institutions are leading the congenital heart defect drug development?
• Which company is leading the congenital heart defect pipeline development activities?
• What is the current congenital heart defect commercial assessment?
• What are the opportunities and challenges present in the congenital heart defect pipeline landscape?
• What is the efficacy and safety profile of congenital heart defect pipeline drugs?
• Which company is conducting major trials for congenital heart defect drugs?
• Which companies/institutions are involved in congenital heart defect collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in congenital heart defect?

Reasons To Buy This Report

The Congenital Heart Defect Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for congenital heart defect. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into congenital heart defect collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Congenital Adrenal Hyperplasia Treatment Market

Congenital Hyperinsulinism (CHI) Pipeline Analysis Report

Congenital Adrenal Hyperplasia (CAH) Epidemiology Forecast